Supplements

Combination therapies (pharmacotherapy plus psychotherapy or acupoint stimulation) show greater efficacy than monotherapies for anxiety, depression, and panic disorder in perimenopausal women, but no single strategy is superior across all outcomes.

This network meta-analysis of 131 RCTs (11,457 perimenopausal women) found that drug_psych ranked highest for reducing HAMD (SUCRA=92.4%), KI (97.9%), SDS (94.5%), PSQI (98.1%), and FSH (96.1%), and for elevating E2 (SUCRA=0.1% for elevation). AcuStim_psych ranked highest for HAMA reduction (93.7%), psych for SAS reduction (98.9%), and drug_AcuStim for clinical efficacy (SUCRA=9.0% for inefficacy) and LH reduction (100%). Safety was highest for control (65.5%).

1 min read•Updated Aug 5, 2026•0 RCTs•1 Meta-analyses•View structured evidence →
Evidence Score49/100
Human RCT☆☆☆☆☆
Meta-analysis★★★☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

Combination therapies (pharmacotherapy plus psychotherapy or acupoint stimulation) show greater efficacy than monotherapies for anxiety, depression, and panic disorder in perimenopausal women, but no single strategy is superior across all outcomes. The current body of evidence comprises 1 study and 1 meta-analysis. EvidenceHub rates the overall confidence at 49/100 (low).

The Claim

Combination therapies (pharmacotherapy plus psychotherapy or acupoint stimulation) show greater efficacy than monotherapies for anxiety, depression, and panic disorder in perimenopausal women, but no single strategy is superior across all outcomes.

This conclusion is most relevant to: Perimenopausal women diagnosed with anxiety, depression, or panic disorder (11,457 participants from 131 RCTs)..

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • ▸Pharmacotherapy, acupoint stimulation, and psychotherapy for perimenopausal women with anxiety, depression, and panic disorder: a systematic review and network meta-analysis of randomized controlled trials. (Frontiers in psychiatry, 2026) —

How It Works

The proposed biological pathway:

  • ▸Perimenopausal hormonal decline (e.g., estrogen drop) contributes to emotional dysregulation.
  • ▸Pharmacotherapy (e.g., antidepressants) modulates neurotransmitter systems.
  • ▸Acupoint stimulation may regulate neuroendocrine pathways.
  • ▸Psychotherapy addresses cognitive and behavioral patterns.
  • ▸Combining modalities may synergistically improve psychological and endocrine outcomes.

Who Might Benefit

Evidence fit by population:

  • ▸Perimenopausal women diagnosed with anxiety, depression, or panic disorder (11,457 participants from 131 RCTs).

Limitations & Caveats

Important context when interpreting this evidence:

  • ▸Network meta-analysis relies on indirect comparisons; heterogeneity across trials may affect robustness.
  • ▸Safety outcomes favored control, suggesting potential adverse events with active treatments, but specific AE profiles were not detailed in the abstract.
  • ▸No single treatment was superior across all outcomes, complicating direct clinical recommendations.

Frequently Asked Questions

Which treatment is best for reducing depression symptoms in perimenopausal women?▼

Combination of pharmacotherapy and psychotherapy (drug_psych) ranked highest for HAMD reduction (SUCRA=92.4%).

Is acupoint stimulation effective for anxiety in perimenopausal women?▼

Yes, combining acupoint stimulation with psychotherapy (AcuStim_psych) ranked highest for HAMA reduction (SUCRA=93.7%).

What is the safest treatment option?▼

The control group had the highest SUCRA for safety (65.5%), indicating that active treatments may have more adverse events, but specific risks were not detailed.

Does combination therapy improve sleep quality in perimenopausal women?▼

Yes, drug_psych ranked highest for PSQI improvement (SUCRA=98.1%), suggesting better sleep outcomes.

References

  1. 1.Zhuang J, Zhou Y, Yu G, Cheng H, Chen X, Qian R. “Pharmacotherapy, acupoint stimulation, and psychotherapy for perimenopausal women with anxiety, depression, and panic disorder: a systematic review and network meta-analysis of randomized controlled trials..” Frontiers in psychiatry, 2026. PMID: 42539596 DOI: 10.3389/fpsyt.2026.1845876
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.